Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada.
Department of Medicine, Jewish General Hospital, McGill University, Montreal, Canada.
Leuk Lymphoma. 2021 Oct;62(10):2352-2359. doi: 10.1080/10428194.2021.1919658. Epub 2021 May 21.
Diagnosis and minimal residual disease (MRD) monitoring of chronic lymphocytic leukemia (CLL) by flow cytometry currently requires multiple antibody panels. We added CD23 and CD200 to the EuroFlow lymphoid screening tube (LST) to create a 10-color modified LST (mLST) capable of diagnosing typical CLL in a single tube. We then explored if the mLST could be used for MRD by comparing its performance to the European Research Initiative on CLL (ERIC) panel using spiked cryopreserved and fresh patient samples. Over 1 year of use in our clinical laboratory, the mLST diagnosed CLL without further immunophenotyping in 56% of samples with an abnormal clone. There was good agreement in MRD results between the mLST and ERIC panels. Therefore, the mLST can streamline CLL diagnosis by reducing technician time and the number of panels required. It may have the potential to screen for MRD in laboratories without access to dedicated panels (ERIC).
通过流式细胞术对慢性淋巴细胞白血病（CLL）进行诊断和微小残留病（MRD）监测目前需要使用多个抗体面板。我们在 EuroFlow 淋巴筛选管（LST）中添加了 CD23 和 CD200，创建了一个能够在单个管中诊断典型 CLL 的 10 色改良 LST（mLST）。然后，我们通过使用添加的冷冻和新鲜患者样本比较其与欧洲慢性淋巴细胞白血病研究倡议（ERIC）面板的性能，探索 mLST 是否可用于 MRD。在我们临床实验室超过 1 年的使用中，mLST 在 56%的异常克隆样本中无需进一步免疫表型分析即可诊断 CLL。mLST 和 ERIC 面板的 MRD 结果具有良好的一致性。因此，mLST 可以通过减少技术人员的时间和所需面板的数量来简化 CLL 的诊断。它有可能在没有专用面板（ERIC）的实验室中筛选 MRD。
